Mitsubishi Tanabe Domestic Struggle Led To Flat Sales And Decreased Profits
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe received significant royalties for multiple sclerosis drug Gilenya (fingolimod), but sales were flat and operating income and profits were down due to a decrease in domestic pharmaceuticals income.